Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 1/20 | 0.46 |
| ▸ | NOTUM | Q6P988 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | LCK | P06239 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30595863 | 1.00 | CFTR (0.46) | CFTRNOTUMMAPTMAPK1ALDH1A1 | |
| SCHEMBL31312487 | 0.89 | CFTR (0.39) | CFTRNOTUMMAPTMAPK1ALDH1A1 | |
| SCHEMBL26742425 | 0.81 | AGBL2 (0.39) | MAPTMAPK1ALDH1A1KMT2AMEN1 | |
| SCHEMBL29488332 | 0.80 | ASPH (0.44) | ALDH1A1KMT2AMEN1 | |
| SCHEMBL23012611 | 0.80 | ASPH (0.44) | ALDH1A1KMT2AMEN1 | |
| SCHEMBL31312141 | 0.80 | MAPK1 (0.38) | CFTRNOTUMMAPTMAPK1ALDH1A1 | |
| SCHEMBL21044587 | 0.79 | NOTUM (0.53) | CFTRNOTUMMAPTMAPK1ALDH1A1 | |
| SCHEMBL29921698 | 0.77 | KMT2A (0.51) | MAPTALDH1A1LMNAKMT2A | |
| SCHEMBL17144499 | 0.75 | MAPK1 (0.50) | MAPK1ALDH1A1LMNA | |
| SCHEMBL160894 | 0.75 | MAPK1 (0.42) | MAPTMAPK1ALDH1A1LMNACYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4727922-A1 | DUAL RAF AND TUBULIN INHIBITORS AND METHODS OF USE THEREOF | Deciphera Pharmaceuticals, LLC (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-4727921-A1 | DUAL RAF AND TUBULIN INHIBITORS AND METHODS OF USE THEREOF | Deciphera Pharmaceuticals, LLC (US) | 2026-04-22 | — | — | EP | disclosed |
| WO-2024263460-A1 | DUAL RAF AND TUBULIN INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC (US) | 2024-12-26 | — | — | WO | disclosed |
| WO-2024258917-A1 | DUAL RAF AND TUBULIN INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC (US) | 2024-12-19 | — | — | WO | disclosed |
| US-20230303570-A1 | KINASE INHIBITORS AND USES THEREOF | ABM THERAPEUTICS CORP (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230303570-A1 | KINASE INHIBITORS AND USES THEREOF | ABM THERAPEUTICS CORP (US) | 2023-09-28 | — | — | US | disclosed |
| CN-116710453-A | Kinase inhibitors and uses thereof | 璧辰医药技术股份有限公司 | 2023-09-05 | — | — | CN | disclosed |
| EP-4192582-A1 | KINASE INHIBITORS AND USES THEREOF | ABM Therapeutics Corporation (US) | 2023-06-14 | — | — | EP | disclosed |
| WO-2022032071-A1 | KINASE INHIBITORS AND USES THEREOF | ABM THERAPEUTICS CORPORATION (US) | 2022-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303570-A1 | KINASE INHIBITORS AND USES THEREOF | ERBB2, ERBB3, ERBB4 | CFTR 2739/4885NOTUM 4508/4885MAPT 2358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.